In Older Hep B Patients, Carcinoma Surveillance Is Advised
Laird Harrison
November 15, 2018
But the risk for the cancer is low enough in younger patients — except for those with cirrhosis — that surveillance might not be warranted, said George Papatheodoridis, MD, PhD, from Athens University Medical School in Greece.
"It will save monitoring in some patients," he told Medscape Medical News.
Long-term monotherapy with entecavir (Baraclude, Bristol-Myers Squibb) or tenofovir disoproxil fumarate (Viread, Gilead) suppresses the hepatitis B virus and improves liver lesions, so the survival rate in patients without compensated cirrhosis is comparable to that in the general population, Papatheodoridis explained here at The Liver Meeting 2018...
Read More: https://www.medscape.com/viewarticle/904951
Free registration may be required
Meeting Coverage
Twitter @Medscape
Recommended Coverage
No comments:
Post a Comment